---
schema_version: "secwatch.filing_event.v1"
accession: "0000886163-26-000048"
form_type: "8-K/A"
ticker: "LGND"
cik: "0000886163"
company_name: "LIGAND PHARMACEUTICALS INC"
filed_at: "2026-09-02T20:08:23+00:00"
generated_at: "2026-09-02T20:10:21.699531+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Ligand files XOMA Royalty financials post-merger; acquired firm lost $41.2M in H1 2026

## Summary
- Merger with XOMA Royalty closed; deal agreement dated April 27, 2026, amended May 16, 2026.
- XOMA Royalty H1 2026 (unaudited): net loss $41.2M, total assets $244.3M, accumulated deficit $1.26B.
- H1 2026 charges: $23.6M impairment, $19.7M credit losses on purchased receivables; income/revenues $29.3M.
- Cash, equivalents, and restricted cash $150.6M at June 30, 2026; liquidity assessed sufficient for at least one year.
- Pro forma combined financial statements filed for periods ended June 30, 2026 and December 31, 2025.

## SEC filing metadata
- accession: 0000886163-26-000048
- form_type: 8-K/A
- ticker: LGND
- cik: 0000886163
- company_name: LIGAND PHARMACEUTICALS INC
- filed_at: 2026-09-02T20:08:23+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/886163/000088616326000048/0000886163-26-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/886163/000088616326000048/lgnd-20260714.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000886163-26-000048
- JSON: https://secwatch.observer/filing/0000886163-26-000048.json
- Plain text: https://secwatch.observer/filing/0000886163-26-000048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.